Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2365-2370

  Tong, X ^a   Arasappan, A ^a   Bennett, F ^a   Chase, R ^a   Feld, B ^a   Guo, Z ^a   Hart, A ^a   Madison, V ^a   Malcolm, B ^a,b   Pichardo, J ^a   Prongay, A ^a   Ralston, R ^a   Skelton, A ^a   Xia, E ^a   Zhang, R ^a   Njoroge, F G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; NARLAPREVIR; PEGINTERFERON ALPHA; PROTEINASE; RIBAVIRIN; SCH 900518; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CROSS RESISTANCE; DRUG MECHANISM; ENZYME INHIBITION; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; REPLICON;

ANTIVIRAL AGENTS; DIPEPTIDES; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HUMANS; INTERFERON ALFA-2B; KINETICS; MUTATION; PROLINE; PROTEASE INHIBITORS; REPLICON; SULFONES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 77952602256     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00135-10     Document Type: Article

References (30)

1. Arasappan, A., F. Bennett, S. L. Bogen, S. Venkatraman, M. Blackman, K. Chen, S. Hendrata, Y. Huang, R. M. Huelgas, L. Nair, A. I. Padilla, W. Pan, R. Pike, P. Pinto, S. Ruan, M. Sannigrahi, F. Velazquez, B. Vibulbhan, W. Wu, W. Yang, A. K. Saksena, V. Girijavallabhan, N. Y. Shih, J. Kong, T. Meng, Y. Jin, J. Wong, P. McNamara, A. Prongay, V. Madison, J. J. Piwinski, K. C. Cheng, R. Morrison, B. Malcolm, X. Tong, R. Ralston, and F. G. Njoroge. Discovery of narlaprevir (SCH 900518): a potent, second generation HCV NS3 serine protease inhibitor. ACS Med. Chem. Lett. doi:10.1021/ml9000276.
2. Beyer, B. M., R. Zhang, Z. Hong, V. Madison, and B. A. Malcolm. 2001. Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity. Proteins 43:82-88.
3. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
4. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
5. Guo, Z., A. Prongay, X. Tong, T. Fischmann, S. Bogen, F. Velazquez, S. Venkatraman, F. G. Njoroge, and V. Madison. 2006. Computational study of the effects of mutations A156T, D168V, and D168Q on the binding of HCV protease inhibitors. J. Chem. Theory Comput. 2:1657-1663.
6. Kolykhalov, A. A., K. Mihalik, S. M. Feinstone, and C. M. Rice. 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 74:2046-2051.
7. Kwo, P., E. J. Lawitz, J. McCone, E. Schiff, J. Vierling, D. Pound, M. Davis, J. Galati, S. Gordon, N. Ravendhran, L. Rossaro, F. Anderson, I. Jacobson, R. Rubin, K. Koury, C. Brass, E. Chaudhri, and J. Albrecht. 2009. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C. J. Hepatol. 50:S4.
8. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M. A. Poupart, J. Rancourt, R. E. Sentjens, R. St. George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
9. Lin, C., K. Lin, Y. P. Luong, B. G. Rao, Y. Y. Wei, D. L. Brennan, J. R. Fulghum, H. M. Hsiao, S. Ma, J. P. Maxwell, K. M. Cottrell, R. B. Perni, C. A. Gates, and A. D. Kwong. 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279:17508-17514.
10. Liverton, N. J., S. S. Carroll, J. Dimuzio, C. Fandozzi, D. J. Graham, D. Hazuda, M. K. Holloway, S. W. Ludmerer, J. A. McCauley, C. J. McIntyre, D. B. Olsen, M. T. Rudd, M. Stahlhut, and J. P. Vacca. 2009. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother. 54:305-311.
11. Lu, L., T. J. Pilot-Matias, K. D. Stewart, J. T. Randolph, R. Pithawalla, W. He, P. P. Huang, L. L. Klein, H. Mo, and A. Molla. 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48:2260-2266.
12. Malcolm, B. A., R. Liu, F. Lahser, S. Agrawal, B. Belanger, N. Butkiewicz, R. Chase, F. Gheyas, A. Hart, D. Hesk, P. Ingravallo, C. Jiang, R. Kong, J. Lu, J. Pichardo, A. Prongay, A. Skelton, X. Tong, S. Venkatraman, E. Xia, V. Girijavallabhan, and F. G. Njoroge. 2006. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother. 50:1013-1020.
13. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965. (Pubitemid 32913521)
14. Morrison, J. F., and C. T. Walsh. 1988. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 61: 201-301.
15. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
16. Perni, R. B., S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, A. Heiser, G. Kalkeri, E. Kolaczkowski, K. Lin, Y. P. Luong, B. G. Rao, W. P. Taylor, J. A. Thomson, R. D. Tung, Y. Wei, A. D. Kwong, and C. Lin. 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50:899-909.
17. Perni, R. B., G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, C. A. Gates, S. L. Harbeson, A. D. Kwong, C. Lin, K. Lin, Y. P. Luong, W. Markland, B. G. Rao, R. D. Tung, and J. A. Thompson. 2003. VX-950: the discovery of an inhibitor of the hepatitis C NS3 4A protease and a potential hepatitis C virus therapeutic. Hepatology 38:972A.
18. Rajagopalan, R., S. Misialek, S. Stevens, D. Myszka, B. Brandhuber, J. Ballard, S. Andrews, S. Seiwert, and K. Kossen. 2009. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry 11:11.
19. Reed, K. E., and C. M. Rice. 2000. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 242:55-84.
20. Reesink, H. W., J. F. Bergmann, J. de Bruijne, C. J. Weegink, J. J. van Lier, A. van Vliet, A. Keung, J. Li, J. O'Mara, M. A. Treitel, E. A. Hughes, H. L. A. Janssen, and R. J. de Knegt. 2009. Safety and antiviral activity of SCH 900518 administered as monotherapy and in combination with peginterferon alfa-2b to naive and treatment-experienced HCV-1 infected patients. J. Hepatol. 50(Suppl. 1):S35.
21. Sarrazin, C., T. L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, M. Welker, D. Wincheringer, Y. Zhou, H. M. Chu, C. Lin, C. Weegink, H. Reesink, S. Zeuzem, and A. D. Kwong. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777. (Pubitemid 46677938)
22. Sarrazin, C., R. Rouzier, F. Wagner, N. Forestier, D. Larrey, S. K. Gupta, M. Hussain, A. Shah, D. Cutler, J. Zhang, and S. Zeuzem. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha- 2b for genotype 1 nonresponders. Gastroenterology 132:1270-1278. (Pubitemid 46627577)
23. Taremi, S. S., B. Beyer, M. Maher, N. Yao, W. Prosise, P. C. Weber, and B. A. Malcolm. 1998. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci. 7:2143-2149.
24. Tong, X., S. Bogen, R. Chase, V. Girijavallabhan, Z. Guo, F. G. Njoroge, A. Prongay, A. Saksena, A. Skelton, E. Xia, and R. Ralston. 2008. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res. 77:177-185.
25. Tong, X., R. Chase, A. Skelton, T. Chen, J. Wright-Minogue, and B. A. Malcolm. 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 70:28-38.
26. Tong, X., Z. Guo, J. Wright-Minogue, E. Xia, A. Prongay, V. Madison, P. Qiu, S. Venkatraman, F. Velazquez, F. G. Njoroge, and B. A. Malcolm. 2006. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry 45:1353-1361. (Pubitemid 43214800)
27. Zeuzem, S., C. Sarrarin, R. Rouzier, A. Tarral, N. Brion, N. Forestier, S. Gupta, D. Deckman, K. Fellows, M. Hussain, D. Cutler, and J. Zhang. 2005. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in HCV-1 patients refractory to pegylated interferon (PEG-IFN- α). Hepatology 42:233A.
28. Zeuzem, S., C. Sarrarin, F. Wagner, R. Rouzier, N. Forestier, S. Gupta, M. Hussain, A. Shah, D. Cutler, and J. Zhang. 2005. Combination therapy with HCV protease inhibitor SCH 503034, plus PEG-Intron in hepatitis C geno-type- 1 PEG-Intron non-responders. Hepatology 42:276A.
29. Zhang, R., B. M. Beyer, J. Durkin, R. Ingram, F. G. Njoroge, W. T. Windsor, and B. A. Malcolm. 1999. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal. Biochem. 270:268-275.
30. Zhou, Y., D. J. Bartels, B. L. Hanzelka, U. Muh, Y. Wei, H. M. Chu, A. M. Tigges, D. L. Brennan, B. G. Rao, L. Swenson, A. D. Kwong, and C. Lin. 2008. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 52:110-120.